Pramlintide, brand name SymlinPen, is an injectable synthetic analogue of the human hormone amylin, used as an adjunct to mealtime insulin to improve blood sugar control in adults with type 1 or type 2 diabetes.
It is specifically for patients who have failed to achieve desired glucose control despite optimal insulin therapy.
Pramlintide mimics the effects of naturally occurring amylin, which is co-secreted with insulin from the pancreatic beta cells after a meal.
It helps regulate blood glucose through three primary mechanisms:
Slows gastric emptying: This limits the rate at which food-derived glucose enters the bloodstream after meals, preventing sharp post-meal blood sugar spikes.
Suppressing glucagon secretion: It inhibits the inappropriate post-meal release of glucagon, a hormone that raises blood sugar, from the pancreas, which in turn reduces hepatic glucose production.
Pramlintide acts on receptors in the brain to promote a feeling of fullness, which can lead to reduced caloric intake and potential weight loss.
Pramlintide is administered by subcutaneous injection immediately before each major meal (one containing at least 250 calories or 30 grams of carbohydrates).
Crucially, pramlintide and insulin must be administered as separate injections and never mixed in the same syringe.
When starting pramlintide therapy, it’s necessary to reduce the patient’s mealtime insulin dose by 50% to minimize the risk of severe hypoglycemia.
Dosage titration: Doses are gradually increased over time based on tolerability and blood glucose control.
Type 1 diabetes: The starting dose is typically 15 mcg, which can be increased in increments (e.g., to 30, 45, or 60 mcg) if no significant nausea occurs for at least three days.
Type 2 diabetes: The starting dose is typically 60 mcg, which can be increased to 120 mcg after 3-7 days if well-tolerated.
The most common side effects are nausea, vomiting, loss of appetite, headache, and fatigue.
Nausea is usually mild to moderate and tends to decrease over time with gradual dose titration.
The most serious risk is severe hypoglycemia, especially in patients with type 1 diabetes, which typically occurs within three hours of injection.
Pramlintide is contraindicated in patients with: A confirmed diagnosis of gastroparesis.
Hypoglycemia unawareness
Poor compliance with their insulin regimen or blood glucose monitoring.